

Tanner Pharma Group and UCB Pharma initiate partnership for epilepsy programme in Southeast Asia

06 October 2025 | News

UCB is developing treatments for severe immune and CNS diseases



Belgium-based UCB Pharma and US-based Tanner Pharma Group have initiated a partnership in Southeast Asia, including countries of Cambodia, Indonesia, Laos, Malaysia, Mongolia, Myanmar, Nepal, Philippines, Singapore, Republic of Korea, Thailand and Vietnam, to enable access to innovative treatments for patients with epilepsy.

“We are proud to work with UCB to provide a means for epilepsy patients in Southeast Asia to access innovative medicines. This partnership reflects the types of companies Tanner strives to associate with,” said Rob Keel, Executive Vice President of the Managed Access Program division at Tanner Pharma.

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Tanner Pharma is a specialist pharmaceutical services provider based in Charlotte, NC, USA with offices in Ireland, Switzerland and the UK. The company has developed a portfolio of service offerings focused on improving the global access to medicines.